According to the HR, the ctDNA profile was a better predictor of PFS than other indicators, such as the tumor diameter, Ann Arbor stage, IPI risk score, TP53 mutation site and IgH/MYC translocation (Table 3). The gene discussed is MYC; the disease is neoplasm.